ADC Therapeutics (ADCT) Shares Outstanding (Weighted Average) (2019 - 2026)

ADC Therapeutics has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $154.1 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $154.1 million, up 43.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.1 million (up 43.79% YoY), and the FY2025 annual result was $127.1 million, up 30.78% from the prior year.
• Shares Outstanding (Weighted Average) came in at $154.1 million for Q1 2026 at ADC Therapeutics, up from $127.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $154.1 million in Q1 2026 to a low of $78.2 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $91.8 million (2024), against an average of $100.4 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 1112.61% in 2022 and increased 2.16% in 2024, its largest moves.
• ADC Therapeutics' Shares Outstanding (Weighted Average) stood at $78.2 million in 2022, then grew by 4.55% to $81.7 million in 2023, then grew by 18.91% to $97.2 million in 2024, then surged by 30.78% to $127.1 million in 2025, then rose by 21.31% to $154.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $154.1 million (Q1 2026), $127.1 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.